BCDIPLOMA
9.3.2022 23:12:12 CET | Business Wire | Press release
How can organisations protect against fraudulent certifications or fake English assessment test results? How can test takers in Europe receive their TOEIC ® test results in one click? How can test takers in Europe be sure that their test results are certified, tamper-proof and secure? To answer these questions, ETS Global, a subsidiary of ETS, chose to collaborate with BCdiploma, the industry-leading company for the digitisation of academic documents via blockchain technology. In Europe, ETS Global and BCdiploma are working on securing hundreds of thousands of digital TOEIC score reports via blockchain. For ETS Global, this is another step in its digital transformation. Starting from January 2022, TOEIC digital score reports are available in France and will be available across Europe during 2022.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220223005682/en/
The result of this collaboration between these two leading players is a digital TOEIC score report that is :
- Secure: the storage of data on the blockchain makes it impossible to falsify the score report. BCdiploma complies with the strictest data protection regulations. In addition to the blockchain's encryption, BCdiploma adds its own secure, patented algorithms. This way, ETS Global and test takers retain full control over their data, which search engines cannot find or list.
- Universal: BCdiploma adapts to all consultation or sharing standards such as Verifiable Credentials from W3C and EBSI, Open Badges, EDCI, and more.
- User-friendly: available online in one click, this digitised document can be downloaded and sent by email, printed or exported in PDF format. A QR code is added to the document, which the test taker or the recipient of the certification can scan.
- Faster : because results are sent by email, test taker receive their scores faster compared to paper score report shipped by post.
- Streamlined: this digitalisation saves time for universities, schools and training organisations. The sending of results to test takers is automated. As for recruiters, they have access to a certified certificate, avoiding the need for inefficient "fact checking" to verify the authenticity of the document.
- More innovative : for the test taker, sending a secure link or a QR code of a certification guarantees quality and presents a modern picture to recruiters.
- More "carbon compatible"*: TOEIC digital score reports are issued using "Avalanche®", the latest generation and one of the most energy-efficient blockchains. Besides, stopping printing score reports will enable ETS Global to save seven trees/year. And without any paper score report to ship to test takers, ETS Global's carbon footprint will decrease by about 490kg of CO2 /year.
Miguel Membrado, Chief Digital Officer of ETS Global says: "The digitalisation of the education sector has been accelerating for years, and even more so since the start of the pandemic. Being able to offer digital TOEIC® test score reports to all ETS Global stakeholders is an obvious choice. We are delighted to be working with BCdiploma, a leading player in this field. As of today, we are offering this service to our test takers in Europe at no additional cost with the goal that within six months, the use of paper score reports in Europe will decline in favour of digital. This is not a war between digital and paper. Our customers will have the choice, of course. But we are convinced of the benefits of digitalisation to the overall customer experience, which this project perfectly illustrates."
Luc Jarry-Lacombe, CEO of BCdiploma, adds: "Our job as a software publisher is to reinvent a diploma that fits into the Digital Workplace. Better yet, it's about bringing the benefits of the blockchain system to test takers, recruiters, and all training organisations and institutions. 50% to 60% of our costs are dedicated to R&D, which enables us to deliver an impeccable service with the latest blockchain technologies. We are very happy to collaborate with the ETS Global teams, to offer more than a diploma: a real quality marketing object."
*already available in France. Deployment in Europe in 2022
About BCdiploma
BCdiploma has been trusted by more than 120 institutions, universities, and businesses in 18 countries. Our patented technology takes advantage of the latest blockchain and distributed storage technologies to deliver a high value Digital Credentials service. Our team brings to institutions a recognised expertise to succeed in their digital transformation projects. https://www.bcdiploma.com/en
About ETS Global
ETS Global B.V., a wholly owned subsidiary of ETS, is the international arm of ETS. At ETS Global B.V., we bring expertise to educational and business communities around the world, including companies, language schools, academic institutions and public service organisations. ETS Global serves 80 countries and offers a range of ETS products, services and learning solutions. https://www.etsglobal.org/fr/en
View source version on businesswire.com: https://www.businesswire.com/news/home/20220223005682/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom